Tiziana Bruno
Research Subjects
Research Interests
Tiziana Bruno has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Antonella Mazzonello
Unità Operativa di Radioterapia Oncologica, Casa di Cura Macchiarella, 90138 Palermo, Italy
1 shared publication - Dario Aiello
Radiation Oncology Division, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy
1 shared publication - Ivan Fazio
Radiation Oncology Unit, CdC Macchiarella, Palermo 90100, Italy, Italy
1 shared publication - Leonarda La Paglia
Unità Operativa di Radioterapia Oncologica, Casa di Cura Macchiarella, 90138 Palermo, Italy
1 shared publication - Lorella Testa
Unità Operativa di Radioterapia Oncologica, Casa di Cura Macchiarella, 90138 Palermo, Italy
1 shared publication - Manuela Federico
U.O. Radioterapia Oncologica, Palermo, Italy
1 shared publication
Latest Publications
- Open Access
- 27 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1030
The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.
- 27 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1030
Open AccessThe Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.